0 285

Cited 3 times in

Outcome of early versus delayed invasive strategy in patients with non-ST-segment elevation myocardial infarction and chronic kidney disease not on dialysis

DC Field Value Language
dc.contributor.author고영국-
dc.contributor.author안철민-
dc.contributor.author최동훈-
dc.contributor.author홍명기-
dc.contributor.author홍성진-
dc.contributor.author김중선-
dc.contributor.author김병극-
dc.contributor.author이승준-
dc.date.accessioned2022-12-22T01:37:12Z-
dc.date.available2022-12-22T01:37:12Z-
dc.date.issued2022-03-
dc.identifier.issn0021-9150-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/191275-
dc.description.abstractBackground and aims: Because of paucity of published data, we evaluated the 2-year major clinical outcomes between early invasive (EI) and delayed invasive (DI) strategies according to the stage of chronic kidney disease (CKD) in patients with non-ST-segment elevation myocardial infarction (NSTEMI), who underwent a successful newer-generation drug-eluting stent (DES) implantation. Methods: A total of 8241 NSTEMI patients were recruited from the Korea Acute Myocardial Infarction Registry (KAMIR). Based on baseline estimated glomerular filtration rate (eGFR; ≥90, 60-89, 30-59, and <30 mL/min/1.73 m2), the patients were classified into groups A (n = 3498), B (n = 3109), C (n = 1178), and D (n = 1178). Thereafter, these 4 groups were sub-classified into the EI and DI groups. Major adverse cardiac events (MACE), defined as all-cause death, recurrent MI (re-MI), and any repeat revascularization, were evaluated. Results: After multivariable-adjusted and propensity score-adjusted analyses, the cumulative incidence of MACE (group A, p = 0.139 and p = 0.103, respectively; group B, p = 0.968 and p = 0.608, respectively; group C, p = 0.111 and p = 0.196, respectively; group D, p = 0.882 and p = 0.571, respectively), all-cause death, re-MI, and any repeat revascularization was similar between the EI and DI groups in the 4 different renal function groups. Conclusions: In the era of newer-generation DES, EI and DI strategies showed comparable major clinical outcomes in patients with NSTEMI and CKD during a 2-year follow-up period. However, to confirm these results, further randomized, large-scale, long-term follow-up studies are needed.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherElsevier-
dc.relation.isPartOfATHEROSCLEROSIS-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHDrug-Eluting Stents*-
dc.subject.MESHHumans-
dc.subject.MESHMyocardial Infarction* / etiology-
dc.subject.MESHMyocardial Infarction* / therapy-
dc.subject.MESHNon-ST Elevated Myocardial Infarction* / diagnosis-
dc.subject.MESHNon-ST Elevated Myocardial Infarction* / therapy-
dc.subject.MESHPercutaneous Coronary Intervention* / adverse effects-
dc.subject.MESHPercutaneous Coronary Intervention* / methods-
dc.subject.MESHRenal Dialysis-
dc.subject.MESHRenal Insufficiency, Chronic* / diagnosis-
dc.subject.MESHRenal Insufficiency, Chronic* / therapy-
dc.subject.MESHTreatment Outcome-
dc.titleOutcome of early versus delayed invasive strategy in patients with non-ST-segment elevation myocardial infarction and chronic kidney disease not on dialysis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorYong Hoon Kim-
dc.contributor.googleauthorAe-Young Her-
dc.contributor.googleauthorMyung Ho Jeong-
dc.contributor.googleauthorByeong-Keuk Kim-
dc.contributor.googleauthorSung-Jin Hong-
dc.contributor.googleauthorSeung-Jun Lee-
dc.contributor.googleauthorChul-Min Ahn-
dc.contributor.googleauthorJung-Sun Kim-
dc.contributor.googleauthorYoung-Guk Ko-
dc.contributor.googleauthorDonghoon Choi-
dc.contributor.googleauthorMyeong-Ki Hong-
dc.contributor.googleauthorYangsoo Jang-
dc.identifier.doi10.1016/j.atherosclerosis.2021.11.024-
dc.contributor.localIdA00127-
dc.contributor.localIdA02269-
dc.contributor.localIdA04053-
dc.contributor.localIdA04391-
dc.contributor.localIdA04403-
dc.contributor.localIdA00961-
dc.contributor.localIdA00493-
dc.contributor.localIdA02927-
dc.relation.journalcodeJ00260-
dc.identifier.eissn1879-1484-
dc.identifier.pmid34924173-
dc.identifier.urlhttps://www.sciencedirect.com/science/article/pii/S0021915021014635?via%3Dihub-
dc.subject.keywordDrug-eluting stent-
dc.subject.keywordNon-ST-segment elevation myocardial infarction-
dc.subject.keywordReperfusion-
dc.contributor.alternativeNameKo, Young Guk-
dc.contributor.affiliatedAuthor고영국-
dc.contributor.affiliatedAuthor안철민-
dc.contributor.affiliatedAuthor최동훈-
dc.contributor.affiliatedAuthor홍명기-
dc.contributor.affiliatedAuthor홍성진-
dc.contributor.affiliatedAuthor김중선-
dc.contributor.affiliatedAuthor김병극-
dc.contributor.affiliatedAuthor이승준-
dc.citation.volume344-
dc.citation.startPage60-
dc.citation.endPage70-
dc.identifier.bibliographicCitationATHEROSCLEROSIS, Vol.344 : 60-70, 2022-03-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.